You may leave me a review on these links:
At GenesisCare, we design personalized care experiences that get the best possible life outcomes. Our new Women’s Center provides multidisciplinary breast health care from mammography to diagnosis to post-treatment follow-up – extending integrated and comprehensive care to the women of our community.
GenesisCare is a first-of-its-kind, global network of over 5,000 dedicated cancer specialists. Our physicians bring the most promising advances in science from across the US and around the world right to your community.
We design care experiences that get the best possible life outcomes. Our purpose and values guide all our actions today and for the future. When you entrust your breast health treatment to GenesisCare, you get the collaboration of thousands of the world’s most brilliant cancer minds. That means successes in Sydney lead to recoveries in Sunnyvale. And advanced research becomes breakthrough treatments.
Innovative treatments focus on precision, accuracy and safety. GenesisCare physicians are at the forefront of research and are continually looking for ways to improve treament options while minimizing patient risks and side effects.
If you are just starting your breast cancer treatment, or you know radiation therapy is required, be sure to speak with a GenesisCare specialist. In close collaboration with your oncologist, we work together to develop the right therapy plan for you, all while leveraging our leading-edge technologies, global clinical trials network and unmatched care experience.
The new 3Dimensions™ system is designed to provide higher quality 3D™ images for radiologists, a more comfortable mammography experience for patients and enhanced workflow for technologists. Discover how sharper images and smarter technologies continue to help find invasive cancers – regardless of age or breast density.1-6
The Horizon DXA system is the latest in densitometry technology, but the dual energy X-ray does more than just measure bone density. The Horizon DXA system has features for a complete fracture risk assessment and more.7
The DCISionRT® test combines the latest innovations in molecular biology to deliver the most advanced Ductal Carcinoma in Situ (DCIS) test available. It is the first biological risk signature developed specifically for DCIS patients and the only test that predicts if you may benefit from radiation therapy. The test looks at the biology of your specific cancer using a comprehensive molecular assessment and determines the risk of your DCIS returning as well as predicting whether you will benefit from treatment.
Your DCISion Score provides valuable information that can be used to help guide your treatment plan with the goal of driving better outcomes. Advanced testing such as DCISionRT® allows you and your clinical team to make a fully informed decision on your next steps for treatment.
AlignRT® is leading-edge technology for surface guided radiation therapy (SGRT) with precise planning software and unique body positioning technologies that enables:
Your comprehensive breast care team includes a radiologist, medical oncologist, breast surgeon, radiation oncologists, radiation therapists, dosimetrists, physicists, nurses and an extended team – all focused on delivering the best possible life outcomes for you.
Dr. Tharian received her medical degree from University of North Texas Health Science Center and her residency and fellowship training at the University of Texas Health Center in San Antonio, TX. She utilizes her depth of experience in academic medicine and patient care to personalize oncology treatment plans for each individual patient.
Dr. Jordan received his medical degree from Kansas City University of Medicine & Biosciences College of Osteopathic Medicine and completed his residency and fellowship at the University of Texas Southwestern Medical School.
Dr. Amosson received his medical degree from the University of Texas Medical Science Center, and completed his chief residency at Baylor University in Waco, TX. He treats a variety of cancer types, specializing in stereotatic body radiotherapy (SBRT) and stereotatic radiosurgery (SRS).
Dr. Garoutte received his medical degree from the University of Iowa College of Medicine in Iowa City. He completed his radiology residency at UT Southwestern/Parkland and fellowship training at UT Southwestern. He has been practicing radiology and breast imaging in the Dallas area since 2001.
Dr. Joshi completed his residency at SUNY Downstate Health Sciences University in Brooklyn, NY and fellowship at Montefiore Medical Center in the Bronx, NYC. He also holds MS degrees in Biomedical Engineering from the University of Michigan, Ann Arbor as well as in Healthcare Management from UT Dallas.
Dr. Nichols earned his undergraduate and medical degrees from the University of Maryland in Baltimore, MD, having completed his residency and fellowship training in radiation oncology at the University of Maryland Medical Center.
References: 1. FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. Zuckerman SP, Conant EF, Keller BM, et al. Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program. Radiology. 2016 Dec;281(3):730-736. 4. Skaane P, Bandos A, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun;271(3):655-63. 5. Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13. 6. McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737-43. 7. https://www.hologic.com/hologic-products/skeletal-solutions/horizon-dxa-system